罗琳
罗琳，女，汉族，1976年6月生，博士，教授，硕士生导师。
教育经历：
1994.09-1999.06南通医学院，临床医学，学士
2001.09-2004.06南通医学院，免疫学学，硕士
2011.09-2015.03浙江大学，药理学，博士
工作经历：
1999.08-至今 南通大学，药理学教师
2018.02-2020.07美国阿拉巴马州立大学，博士后
研究方向：
免疫药理学，中药药理学，消化系统疾病机制及治疗研究
基金项目：
1.国家自然科学基金委员会，面上项目，82170544,肠道炎症中转录因子Blimp1对滤泡调节性T细胞（Tfr）稳态的调控作用及机制研究，2022-01-01至2025-12-31，在研，主持。
2. National Institutes of Health(NIH), R01, AI148711, Contribution of the Effector Treg-B-antibody Nexus to the Regulation of CNS autoimmunity, 2020-06至2025-05，在研，参与。
3.南通市科技局，基础科学研究计划，JC2020039,转录因子Blimp1调控调节性T细胞功能和代谢在肠道炎症中的作用，2020-10至2022-10，结题，主持。
4. United States Department of Defense (DOD), PRCRP Career Award, W81XWH-18-1-0315, Boosting the systemic and in situ CD4+ T-cell responses to malignant glioma by oncolytic HSV virotherapy, 2018-09至2022-08，结题，参与。
5.江苏省科技厅，社会发展-面上项目, BE2018674，基于茵陈蒿汤的中药经典名方现代开发应用研究，2018-05至2022-02，结题，参与。
6.南通市应用基础研究计划课题，MS12015152，毒蕈碱型乙酰胆碱受体对肝损伤和纤维化的作用及机制研究，已结题，主持。
7.国家自然科学基金青年科学基金项目，31300893，鱼藤酮影响溶酶体膜通透性引发α-突触核蛋白自噬性降解障碍导致帕金森症的机制探讨，已结题，参与。
8.国家自然科学基金面上项目，30971117，瘦素对抑制肝星状细胞激活的关键转录因子SREBP1c的影响，已结题，参与。
9.南通市应用基础研究计划课题，K2009029，芍药苷对胆汁淤积性肝损伤的保护作用及其机理研究，已结题，主持。
10.江苏省教育厅自然科学课题，08KJB360009，谱效关系与体内成分相结合的茵陈蒿汤药效物质基础研究，已结题，主持。
11.南通市科技局课题，K2006022，赤芍治疗黄疸型肝炎有效部位筛选及提取工艺研究，已结题，主持。
科研成果：
近5年主要关注自身免疫性疾病和肿瘤中T细胞调控机制研究。课题组主要应用模式动物，分子生物学、组织与细胞形态学、多色流式细胞分析技术等多种手段探讨T细胞等免疫细胞对肿瘤和免疫炎症的影响及其机制。
研究工作受到国家自然科学基金委员会，江苏省教育厅和南通市科技局基金项目支持，同时参与了肿瘤免疫和自身性免疫疾病相关美国NIH和DOD课题研究，取得了一些具有意义的成果，其中有关调节性T细胞的稳定性调控分子机制及其对疾病影响的研究，为自身免疫性炎症和肿瘤病理生理学机制及治疗药物的开发提供了理论探索。
在Nature Cancer、Molecular Cancer、J Neuroinflammation、Cell Reports、Free Radical Biology and Medicine、Biochimica et Biophysica Acta、Toxicology and Applied Pharmacology、Cells、European Journal of Pharmacology、American Journal of Chinese Medicine、Journal of Gastroenterology and Hepatology等期刊发表专业学术论文多篇，其中中科院TOP期刊5篇，1区论文3篇，2区论文8篇，论文累积被引2000余次。
成果奖励：
1.赤芍治疗黄疸型肝炎有效部位筛选及提取工艺研究，南通市科技进步三等奖，2010.10.30，排名第一。
2.五味子中木脂素类成分分析及血清药化学研究，南通市科技进步三等奖，2015.12.01，排名第二。
3.血清药理学与血清药化学相结合研究中药复方药效物质基础，江苏省中医药科技进步奖，三等奖，2011.10.30，排名第四。
代表性论文：
1. Xu L, Jiang Y, Xu F, Liu J, Jiang Y, Fang F, Luo L*. Deucravacitinib and shikonin combination therapy ameliorates imiquimod-induced psoriasis in mice. Int J Immunopathol Pharmacol. 2024 March;38:3946320241260262.
2. Feng Y, Wang J, Liu J, Zhou Y, Jiang Y, Zhou W, Wu F, Liu X, Luo L*.Mecp2 Deficiency in Peripheral Sensory Neuron Improves Cognitive Function by Enhancing Hippocampal Dendritic Spine Densities in Mice. Cells. 2024 Jun 6;13(11):988.
3. Luo L, Leavenworth JW. Analysis of the In Vivo Function of Follicular Regulatory T (TFR) Cells in the Regulation of Antibody Response. Methods Mol Biol. 2023;2559:3-13.
4. Xiaoyan Ren#, Gaoshan Zhang#, Xiang Ling, Linhua Zhang, Yangyang Tian, Guoxiang Zhu, Pengbo Wang, Jianmei W. Leavenworth, Lin Luo*, Fengzhi Li*. Allyl-isothiocyanate Against Colorectal Cancer via the Mutual Dependent Regulation of p21 and Nrf2. European Journal of Pharmacology. 2023, 957, 176016.
5. Liuliu Mao; Jun Chen; Kang Cheng; Zhihua Dou; Jonathan D. Leavenworth; Hengyue Yang; Diyuan Xu; Lin Luo*. Nrf2-Dependent Protective Effect of Paeoniflorin on α-Naphthalene Isothiocyanate-Induced Hepatic Injury, American Journal of Chinese Medicine, 2022, 5(05): 1331-1348.
6. Michael L. Dixon; Lin Luo; Sadashib Ghosh; Jefrey M. Grimes; Jonathan D. Leavenworth and Jianmei W. Leavenworth. Remodeling of the tumor microenvironment via disrupting Blimp1+ effector Treg activity augments response to anti-PD-1 blockade. Molecular Cancer,2021,20:150.
7. Zhang Z#, Luo Lin#, Xing C, Chen Y, Xu P, Li M, Zeng L, Li C, Ghosh S, Della Manna D, Townes T, Britt WJ, Wajapeyee N, Sleckman BP, Chong Z, Leavenworth JW, Yang ES. RNF2 ablation reprograms the tumor-immune microenvironment and stimulates durable NK and CD4 + T-cell-dependent antitumor immunity. Nature Cancer, 2021, 2(10):1018-1038.
8. Luo Lin; Hu Xianzhen; Michael Dixon; Brandon J. Pope; Jonathan D. Leavenworth; Chander Raman; William R. Meador; Jianmei W. Leavenworth. Dysregulated follicular regulatory T cells and antibody responses exacerbate experimental autoimmune encephalomyelitis, Journal of Neuroinflammation, 2021, 18(27): 1-15.
9. Erxia Shen#, Hardis Rabe#, Lin Luo#, Lei Wang, Qin Wang, Jie Yin, Xueying Yang, Wenquan Liu, Jessic M. Sido, Hidetoshi Nakagawa, Lin Ao, Hye-Jung Kim, Harvey Cantor, Jianmei W. Leavenworth. Control of Germinal Center Localization and Lineage Stability of Follicular Regulatory T Cells by the Blimp1 Transcription Factor. Cell Reports. 2019, 29(7): 1848–1861.
10. Lin Luo* ; Gaoshan Zhang ; Liuliu Mao ; Pengbo Wang; Chenghao Xi; Gaoyong Shi; Jianmei W. Leavenworth*. Group II muscarinic acetylcholine receptors attenuate hepatic injury via Nrf2/ARE pathway, Toxicology and Applied Pharmacology, 2020, 395(15): 114978.
11. Luo Lin ; Chen Yeru ; Wang Hongyan ; Wang Shengcun; Liu Kaihua; Li Xin; Wang Xiu Jun ; Tang Xiuwen. Mkp-1 protects mice against toxin-induced liver damage by promoting the Nrf2 cytoprotective response , Free Radical Biology and Medicine, 2018, 115: 361-370.
12. Pengbo Wang#; Lin Luo#; Qiusheng Shen; Gaoyong Shi; Anaz Mohammeda; Songshi Ni; Xiang Wu. Rosuvastatin improves myocardial hypertrophy after hemodynamic pressure overload via regulating the crosstalk of Nrf2/ARE and TGF-β/ smads pathways in rat heart. European Journal of Pharmacology, 2018, 820: 173–182.
13. Lin Luo; Chenghao Xi; Tingting Xu; Gaoshan Zhang; E Qun; Wei Zhang. Muscarinic receptor mediated signaling pathways in hepatocytes from CCL4 -induced liver fibrotic rat, European Journal of Pharmacology, 2017, 807:109-116.
14. Lin Luo; Tingting Xu; Pengbo Wang; Liuliu Mao; Chenghao Xi; Jinhua Huang; Wei Zhang. Expression of muscarinic acetylcholine receptors in hepatocytes from rat fibrotic liver. Experimental and Toxicologic Pathology. 2017, 69: 73–81.
15. Syed Minhaj Uddin Ahmed#; Lin Luo#; Akhileshwar Namani; Xiu Jun Wang; Xiuwen Tang. Nrf2 signaling pathway: Pivotal roles in inflammation. Biochimica et Biophysica Acta. 2017, 1863: 585–597.
16. Lin Luo; Yeru Chen; Deqi Wu; Jiafeng Shou; Shengcun Wang; Jie Ye; Xiuwen Tang ; XiuJun Wang. Butylated hydroxyanisole induces distinct expression patterns of Nrf2 and detoxification enzymes in the liver and small intestine of C57BL/6 mice, Toxicology and Applied Pharmacology, 2015, 288(3): 339-348.
17. Lin Luo, Zhou Ailing. Antifibrotic activity of anisodamine in vivo is associated with changed intrahepatic levels of matrix metalloproteinase-2 and its inhibitor tissue inhibitors of metalloproteinases-2 and transforming growth factor beta1 in rats with carbon tetrachloride-induced liver injury. Journal of Gastroenterology and Hepatology. 2009, 24(6):1070-6.